menu search

HLN / GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion. Read More
Posted: Jan 3 2023, 09:01
Author Name: Zacks Investment Research
Views: 111866

HLN News  

Haleon down as sales and earnings marginally undershoot - maintains full-year outlook

By Proactive Investors
November 2, 2023

Haleon down as sales and earnings marginally undershoot - maintains full-year outlook

Haleon PLC (LSE:HLN, NYSE:HLN)'s stock took a 2.6% hit in early trading, erasing roughly £800 million in market value, following the company's third- more_horizontal

Advil maker Haleon's quarterly revenue rises on price hikes, strong demand

By Reuters
November 2, 2023

Advil maker Haleon's quarterly revenue rises on price hikes, strong demand

Consumer healthcare company Haleon posted higher third-quarter revenue and stuck by its full-year forecasts on Thursday, helped by price hikes and res more_horizontal

Sanofi to create its own Haleon, Kenvue as its stock price tumbles

By Invezz
October 27, 2023

Sanofi to create its own Haleon, Kenvue as its stock price tumbles

Sanofi (FRA: SNW), the giant healthcare company, is considering spinning off its consumer health business. In a statement, the management said it was more_horizontal

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

By Seeking Alpha
September 7, 2023

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon's share price has slumped, but its performance is relatively better compared to its consumer staples peers and the recent listing Kenvue. HLN h more_horizontal

Haleon Upgrades Full-Year Sales Forecasts As Recent Trading Impresses

By Forbes
August 2, 2023

Haleon Upgrades Full-Year Sales Forecasts As Recent Trading Impresses

The FTSE 100 healthcare firm said that revenues increased 10.6% in the first half, while pre-tax profit increased 11.1% year on year. more_horizontal

Haleon upgrades guidance after strong first half

By Proactive Investors
August 2, 2023

Haleon upgrades guidance after strong first half

British consumer healthcare giant, Haleon PLC (LSE:HLN, NYSE:HLN), has upgraded its full-year sales and earnings guidance for 2023, reflecting a solid more_horizontal

Haleon raises annual organic revenue growth forecast on steady demand

By Reuters
August 2, 2023

Haleon raises annual organic revenue growth forecast on steady demand

Haleon on Wednesday raised its forecast for annual organic revenue growth as the consumer healthcare company is confident that demand for its oral and more_horizontal

BAE and Haleon earnings lead the way on Wednesday

By Proactive Investors
August 1, 2023

BAE and Haleon earnings lead the way on Wednesday

Defence contractor BAE Systems PLC (LSE:BA.) reports half-year numbers fresh from winning a host of contracts, including from the UK, Israel and Sa more_horizontal


Search within

Pages Search Results: